2seventy Bio, Inc.

Pfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these

Bristol Myers Squibb is moving to take over its longtime cell therapy partner 2seventy bio and the CAR-T cell therapy they developed and commercialized together, Abecma (idecabtagene vicleucel). The b

Amid the risk of a debt default due to a shortage of capital, bluebird bio has decided to quit the public markets and go private, with private equity firms Carlyle and SK Capital Partners acquiring it

The analytical tools encompassed by the concept of real-world evidence are growing increasingly valuable for enhancing early-stage drug development, an area receiving less attention than pivotal trial